Generics 4

Biosimilars

Medical devices

Nutraceuticals

Filters

Leuprorelin manufacturers

4 products found

Filters

4 products found

leuprorelin

Injection, pre-filled syringe 11.25mg

Dossier type
CTD
Country of origin
European Union
Dossier status
Ready
GMP approvals
EU GMP
Unavailable markets
Algeria, Bahrain, Egypt, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Qatar, Saudi Arabia, Sudan, Syria, Tunisia, United Arab Emirates, Yemen
Registered in
Germany

Manufacturer #8191

A pharmaceutical manufacturer based in Europe that has been active in 10+ countries selling its products in Europe, North America, Asia, MENA, and LATAM for 10+ years. The main therapeutic areas include oncology and immunology. The company's production lines are GMP-compliant. The company possesses branches in Europe and MENA.

Manufacturer usually replies in 9 days

leuprorelin

Vials, injection 3.75mg, 7.5mg, 11.25mg, 22.5mg, 30mg

Dossier type
CTD
Country of origin
Argentina
Dossier status
Ready
GMP approvals
FDA, EU GMP, ANVISA, INVIMA
Unavailable markets
Argentina, Austria, Belgium, Bolivia, Brazil, Bulgaria, Chile, Colombia, Croatia, Cuba, Cyprus, Czech Republic, Denmark, Dominican Republic, Ecuador, Estonia, Finland, France, Germany, Greece, Guatemala, Haiti, Hungary, Indonesia, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Mexico, Netherlands, Peru, Philippines, Poland, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom, Venezuela, South Africa
Registered in
Georgia, Bosnia and Herzegovina, Indonesia, Philippines

Manufacturer #11475

The company is situated in South America and over time has expanded producing oncology drugs for Latin America, Asia Pacific, Europe, and North America, including the United States. The goal of the company is to develop and produce high-quality oncology generics and generics with value-added technology or super generics. Part of the goal is also to produce efficient processes that allow us to have competitive prices.

Manufacturer usually replies in 4 days

leuprorelin

Injection, pre-filled syringe 22.5 mg, 45 mg

Dossier type
CTD
Country of origin
Guatemala
Dossier status
Ready
GMP approvals
Guatemala

Manufacturer #15114

A private company who have been in the market since the 1900s. A leading company with one of the fastest growth in terms of perspective. A leading pharmaceutical company that has innovativeness and affordable medical services at its core.

Manufacturer usually replies in 9 days

Want to view all 4 products? Create your free account today!

Leuprorelin

Leuprorelin, also called Leuprolide, is a manufactured version of a hormone used to treat prostate cancer, breast cancer, endometriosis, uterine fibroids, and early puberty. It is also indicated in the treatment of estrogen-dependent conditions such as endometriosis or uterine fibroids. It may be used to prevent premature ovulation in cycles of controlled ovarian stimulation for IVF amongst teens with precocious puberty in both males and females. In combination with other drugs, it delays puberty in transgender youth until they are old enough for hormone replacement therapy. Leuprorelin is sold under the brand name Lupron among others. Bayer AG markets Leuprorelin under the brand name Viadur. It is also marketed by Tolmar under the brand names Eligard and Fensolvi and by TAP Pharmaceuticals and Abbott as Lupron. It was first patented in 1973, and approved for sales in the United States in 1985. It is on the World Health Organization's List of Essential Medicines. Leuprorelin use is off-label, for not having the approval of the Food and Drug Administration and without data on long- term effects of this use. In Europe, In the UK and Ireland, Takeda UK, as Prostap SR and Prostap 3, markets it.

Forms and Dosage

Leuprorelin is sold as a slow-release implant or subcutaneous/intramuscular injection. It is sold as Short-acting daily intramuscular injection or as a Long-acting depot intramuscular injection or as a Long-acting depot subcutaneous injection or Long-acting subcutaneous injection or a Long-acting subcutaneous implant. In the treatment of Advanced Prostate Cancer, a standard dose is 7.5 mg IM monthly or 22.5 mg IM every 3 months or 30 mg IM every 4 months, or 45 mg IM every 6 months. In the treatment of Endometriosis, the dose is 3.75 mg IM monthly for up to 6 months or 11.25 mg IM every 3 months for 2 doses for a total of 6 months.

How does it work?

Leuprorelin is a gonadotropin-releasing hormone analogue that acts as an agonist at pituitary GnRH receptors. Initially, Agonism of GnRH receptors results in the stimulation of luteinizing hormone and follicle-stimulating hormone secretion by the anterior pituitary eventually leading to increased serum estradiol and testosterone levels via the normal physiology of the hypothalamic–pituitary–gonadal axis. But, Pituitary GnRH receptors become de-sensitised after weeks of continuous therapy. This protracted down-regulation of GnRH receptor activity is the key objective of Leuprorelin therapy and ultimately results in decreased LH and FSH secretion, leading to Hypogonadism and thus a dramatic reduction in estradiol and testosterone levels regardless of sex. while treating prostate cancer, the initial increase in testosterone levels can be associated with Leuprorelin therapy is counterproductive to treatment goals.

Finding Leuprorelin Manufacturers and Suppliers

The process of finding trusted Leuprorelin manufacturers and Leuprorelin suppliers can be made simpler, quicker and more accessible by using Pipelinepharma's online platform, a B2B marketplace that lets you finalize the deals of pharmaceutical products in a matter of a few clicks. Also, it is an easy to use online platform to grow your business opportunities. The robust search engine makes it convenient to search for manufacturers and suppliers of Leuprorelin. The search can be further refined with industry-specific filters such as dossier type, country of origin, GMP approvals, and search criteria for Wholesaler, etc. helping to get in contact with the preferred manufacturer and supplier readily.